Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $29.25.

A number of analysts have weighed in on EYPT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Thursday, January 22nd. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Mizuho set a $28.00 price target on Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Finally, Royal Bank Of Canada upped their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th.

Insider Activity

In other news, insider Ramiro Ribeiro sold 42,544 shares of Eyepoint Pharmaceuticals stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a total transaction of $727,502.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its position in shares of Eyepoint Pharmaceuticals by 13.5% in the 4th quarter. The Manufacturers Life Insurance Company now owns 22,775 shares of the company’s stock valued at $416,000 after buying an additional 2,711 shares during the last quarter. Bleichroeder LP increased its position in Eyepoint Pharmaceuticals by 23.4% during the 4th quarter. Bleichroeder LP now owns 316,515 shares of the company’s stock valued at $5,783,000 after purchasing an additional 60,000 shares during the period. Rafferty Asset Management LLC bought a new position in Eyepoint Pharmaceuticals during the 4th quarter worth approximately $255,000. Alyeska Investment Group L.P. raised its holdings in Eyepoint Pharmaceuticals by 289.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 784,403 shares of the company’s stock worth $14,331,000 after purchasing an additional 583,055 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 22.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 648,565 shares of the company’s stock worth $11,849,000 after purchasing an additional 116,842 shares during the period. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Trading Down 0.5%

EYPT opened at $12.94 on Monday. The company’s 50 day moving average is $15.95 and its 200-day moving average is $13.78. The company has a market cap of $1.07 billion, a P/E ratio of -4.33 and a beta of 1.76. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.